SNY Jan 2025 57.500 put
| Previous close | 10.60 |
| Open | 10.60 |
| Bid | 5.80 |
| Ask | 9.40 |
| Strike | 57.50 |
| Expiry date | 2025-01-17 |
| Day's range | 10.60 - 10.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 148 |
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
Investor's Business DailyAstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.
- Reuters
UPDATE 2-Sanofi profit slips on generic competition and currency effects
Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.
